drugset / Trial / NCT04636515
A Phase Ⅱ Study of F520 in Patients With Urothelial Carcinoma
NaSingle-groupOpen-labelTreatment
Summary
This is a multicenter, Phase 2 study to evaluate the efficacy and safety of the anti- programmed cell death-1(PD-1) monoclonal antibody F520 in participants with locally advanced or metastatic Urothelial Cancer (UC).
Timeline
- Start
- 2021-01
- Primary completion
- 2022-03
- Completion
- 2022-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | F520 | Monoclonal antibody | 200 mg | — |